<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00418509</url>
  </required_header>
  <id_info>
    <org_study_id>CFOR258H2104</org_study_id>
    <nct_id>NCT00418509</nct_id>
  </id_info>
  <brief_title>Study of Mometasone Furoate/Formoterol Fumarate Inhalation Combination in Healthy Volunteers</brief_title>
  <official_title>A Randomized, Single Dose, 3-Period Crossover Study to Evaluate the Dosage Form Proportionality, Dose Proportionality and Pharmacokinetics of Mometasone Furoate and Formoterol Fumarate From Three Combination MDI Formulations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will compare the performance of three combination metered dose inhalation devices
      and the variability of mometasone and formoterol doses delivered to the lungs in a healthy
      volunteer population
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dosage form and dose proportionality of mometasone and formoterol from combination metered dose inhalers (MDI).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Extrapulmonary (systemic) effects and safety of mometasone and formoterol from combination MDI formulations.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma and urine concentrations mometasone and formoterol</measure>
  </secondary_outcome>
  <enrollment>24</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone furoate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol fumarate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, male or female subjects age 18 to 65 years of age (included)

          -  In good health as confirmed by past medical history

          -  Female subjects must be either surgically sterilized at least 6 months prior to study
             participation or post-menopausal (no regular menstrual bleeding for at least 2 years)

          -  Body mass index (BMI) within the range of 18.5 to 32 kg/m2 and weigh at least 50 kg

          -  Able to communicate well with the investigator, to understand and comply with the
             requirements of the study

          -  Understand and sign the written informed consent

        Exclusion Criteria:

          -  Smokers (use of tobacco products in the previous 1 year with a pack year history of no
             greater than 10 pack years).

          -  Female subjects who are pregnant, or lactating

          -  Treatment with any oral or intravenous corticosteroids within 1 month of the first
             study treatment.

          -  Patients with a current respiratory tract infection or one within 1 month prior to
             screening.

          -  Patients with a history of malignancy, myocardial infarction, untoward reactions to
             sympathomimetic amines or inhaled medicine.

        Subjects with a current or history of a clinically significant cardiac arrhythmia.

          -  Participation in any clinical investigation within 4 weeks prior to dosing or longer
             if required by local regulation.

          -  Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing.

          -  Significant illness within the two weeks prior to dosing.

          -  A past medical history of clinically significant ECG abnormalities.

          -  History of fainting, known hypersensitivity to the study drug or drugs similar to the
             study drug. any surgical or medical condition which might significantly alter the
             absorption, distribution, metabolism or excretion of drugs or which may jeopardize the
             subject in case of participation in the study, immunocompromise, including a positive
             HIV (ELISA and Western blot) test result, positive Hepatitis B surface antigen (HBsAg)
             or Hepatitis C test result, drug or alcohol abuse within the 12 months prior to dosing
             or evidence of such abuse as indicated by the laboratory assays conducted during the
             screening evaluations.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Principal Investigator</role>
    <affiliation>Investigator site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Horsham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2007</study_first_submitted>
  <study_first_submitted_qc>January 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2007</study_first_posted>
  <last_update_submitted>June 21, 2007</last_update_submitted>
  <last_update_submitted_qc>June 21, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2007</last_update_posted>
  <keyword>Dose proportionality</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>mometasone</keyword>
  <keyword>formoterol</keyword>
  <keyword>Healthy volunteers study</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

